Bronchopulmonary Dysplasia (BPD)
30
6
7
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
3.3%
1 terminated out of 30 trials
91.7%
+5.1% vs benchmark
20%
6 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (30)
Efficacy of Intrathecal Administration of Budesonide to Prevent Bronchopulmonary Dysplasia
Continued Pressure for Alveolar Protection (CPAP Trial)
PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
National Surveillance and Prevention of Neonatal VAP
Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants
Oral Vitamin A Supplementation for Prevention of Bronchopulmonary Dysplasia in Preterm Infants
The Budesonide in Babies (BiB) Trial
Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
Impact of the Early Life Virome Development on Bronchopulmonary Dysplasia in Preterm Neonates
Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?
Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality
Combined Oscillation-Volume guarantEe Study
Metformin for Premature Infants With Bronchopulmonary Dysplasia
Dexamethasone Regimens for BPD Prevention in Preterm Infants
Long-Term Burden of BPD and Health-Related Quality of Life (BronQ Family)
Transfusion of Prematures Trial
The Correlation Between Red Cell Transfusion and Complications of Prematurity
Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants
Chloride Imbalance in Preterm Infants
Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial